Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ)   2013 , Volume 15 , Number 1; Page(s) 49 To 57.
 
Paper: 

LONG-TERM RESULTS OF STEREOTACTIC BRACHYTHERAPY (TEMPORARY 125IODINE SEEDS) FOR THE TREATMENT OF LOW-GRADE ASTROCYTOMA (GRADE II)

 
 
Author(s):  SHAHZADI SOHRAB, AZIMI PARISA*, PARSA KHOSROW
 
* DEPARTMENT OF NEUROSURGERY, SHAHID-BEHESHTI UNIVERSITY OF MEDICAL SCIENCE, TEHRAN, IR IRAN
 
Abstract: 

Background: Treatment of low-grade astrocytoma (WHO grade II) (LGA II) remains a challenge. There is limited information regarding the long-term effects of stereotactic brachytherapy (SBT) (temporary 125Iodine seeds) on patients with LGA II.
Objectives: The purpose of this study was to evaluate disease control and survival after stereotactic brachytherapy in patients with circumscribed and relatively small size tumors.
Materials and Methods: A retrospective review of 29 patients, treated between 1991 and 2011, was conducted to evaluate survival, complications, and local disease control after stereotactic brachytherapy. They belonged to a larger group of 48 cases with low-grade gliomas, treated with stereotactic brachytherapy. The demographic and clinical characteristics in patients including age, sex, and survival time were extracted from records.
Results: Thirteen patients were male and 16 were female, with the median age of 29 years (range, 2.5 – 64 years). The median follow-up was 95 (range, 6-240) months. Based on Pignatti classification, 10 patients were at low- and 19 patients at high-risk. The median overall as well as progression-free survivals for patients were 135 months (95% con?dence interval: 76 – 194) and 96 months (95% con?dence interval: 1 – 199), respectively. Five- and 10-year progression-free survivals were 41.4 % and 34.5 %, respectively, and the 5- and 10-year overall survivals were 65.5 % and 44.8%, respectively. Progression-free survival was not significantly higher in smaller size tumors (P
=0.224), nor for spherical versus no nspherical tumors (P=0.307). There was no treatment-related morbidity after stereotactic brachytherapy, and no radiogenic complications occurred during the follow-up period. Mortality due to tumor progression occurred in 4 patients (14%), and 11 patients were alive at the last follow-up.
Conclusions: The stereotactic brachytherapy for patients with circumscribed and relatively small size tumors appears to be a safe, feasible, and minimally-invasive treatment.

 
Keyword(s): SURVIVAL, LONG-TERM, ASTROCYTOMA, BRACHYTHERAPY
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 71
 
Latest on Blog
Enter SID Blog